To the Editor: In the March 15, 2008, issue of Clinical Cancer Research , Sitnikova et al. ([1][1]) reported that IMP3 is an independent prognostic marker and can help predict disease progression in patients with superficial urothelial carcinomas of the bladder. Interestingly, over the past few
No takes yet. Share an insight, caveat, or question.
Shailendra N. Kapoor (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: